ES2031805T1 - Derivados del t-4 soluble. - Google Patents
Derivados del t-4 soluble.Info
- Publication number
- ES2031805T1 ES2031805T1 ES198989103297T ES89103297T ES2031805T1 ES 2031805 T1 ES2031805 T1 ES 2031805T1 ES 198989103297 T ES198989103297 T ES 198989103297T ES 89103297 T ES89103297 T ES 89103297T ES 2031805 T1 ES2031805 T1 ES 2031805T1
- Authority
- ES
- Spain
- Prior art keywords
- sequence
- amino acid
- around
- polypeptide
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010061598 Immunodeficiency Diseases 0.000 abstract 2
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000007813 immunodeficiency Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- -1 AMINO Chemical class 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/821—Separation of nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ESTE INVENTO PROVEE UN AGENTE TERAPEUTICO CAPAZ DE FORMAR ESPECIFICAMENTE UN COMPLEJO CON VIRUS DE INMUNODEFICIENCIA HUMANA ENVOLTURA DE GLICOPROTEINA QUE COMPRENDE UN POLIPEPTIDO. EN UNA FASE DEL INVENTO LA SECUENCIA DEL AMINOACIDO DE EL POLIPEPTIDO COMPRENDE LA SECUENCIA DEL AMINOACIDO MOSTRADA EN LA FIGURA 6 DESDE ALREDEDOR DE +3 A +185 FUSIONADO A LA SECUENCIA DEL AMINOACIDO DESDE ALREDEDOR DE +351 A +369. EN OTRA FASE DEL INVENCTO LA SECUENCIA COMPRENDE LA SECUENCIA DEL AMINOACIDO MOSTRADA EN LA FIGURA 6 DESDE ALREDEDOR DE +3 A +106 FUSIONADO A LA SECUENCIA DEL AMINPOACIDO DESDE ALREDEDOR DE +351 A +369. EN UNA FASE TODAVIA MAS AVANZADA LA SECUENCIA DEL AMINOACIDO DEL POLIPEPTIDO COMPRENDE LA SECUENCIA DEL AMINOACIDO MOSTRADA EN LA FIGURA 6 DESDE ALREDEDOR DE +3 A +185. ESTE INVENTO PROVEE ASI MISMO DE UN METODO PARA EL TRATAMIENTO DE UN SUJETO INFECTADO CON VIRUS DE INMUNODEFICIENCIA HUMANO. EL METODO COMPRENDE LA ADMINISTRACION AL SUJETO DE UNA CANTIDAD EFECTIVA DE UNA COMPOSICIONFARMACEUTICA QUE COMPRENDE UNA CANTIDAD EFECTIVA DE UN AGENTE TERAPEUTICO DEL INVENTO Y DE UN PORTADOR FARMACEUTICAMENTE ACEPTABLE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/160,348 US5110906A (en) | 1986-08-21 | 1988-02-24 | Derivatives of soluble T-4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2031805T1 true ES2031805T1 (es) | 1993-01-01 |
Family
ID=22576514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES198989103297T Pending ES2031805T1 (es) | 1988-02-24 | 1989-02-24 | Derivados del t-4 soluble. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5110906A (es) |
| EP (1) | EP0330227A3 (es) |
| JP (1) | JPH02503269A (es) |
| KR (1) | KR900700592A (es) |
| AU (1) | AU628072B2 (es) |
| DE (1) | DE330227T1 (es) |
| DK (1) | DK175816B1 (es) |
| ES (1) | ES2031805T1 (es) |
| FI (1) | FI102837B (es) |
| GR (1) | GR900300099T1 (es) |
| HU (1) | HU213019B (es) |
| NZ (1) | NZ228127A (es) |
| PT (1) | PT89838B (es) |
| WO (1) | WO1989008143A1 (es) |
| ZA (1) | ZA891456B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE135747T1 (de) | 1986-08-21 | 1996-04-15 | Univ Columbia | Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids |
| US6673896B1 (en) * | 1986-08-21 | 2004-01-06 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
| US5958678A (en) * | 1986-08-21 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS |
| ZA887365B (en) * | 1987-10-02 | 1990-05-30 | Genentech Inc | Adheson variants |
| US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
| EP0408372A1 (en) * | 1989-07-13 | 1991-01-16 | Smithkline Beecham Corporation | Anti-viral therapy |
| EP0432693A1 (en) * | 1989-12-11 | 1991-06-19 | Sumitomo Chemical Company, Limited | Liposomes cytotoxic to virus-infected cells |
| JPH0725794B2 (ja) * | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
| EP0491888A4 (en) * | 1990-05-25 | 1992-09-02 | Biogen, Inc. | Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection |
| AU9028791A (en) * | 1990-10-05 | 1992-04-28 | President And Fellows Of Harvard College | Detection and isolation of ligands |
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US6274134B1 (en) | 1992-01-29 | 2001-08-14 | National Institutes Of Health | Human cell adhesion protein AAMP-1 and uses thereof |
| US5750394A (en) * | 1994-05-20 | 1998-05-12 | The Mount Sinai Medical Center | Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication |
| US5635351A (en) * | 1995-03-14 | 1997-06-03 | The Regents Of The University Of California | Genetic gain and loss in gliomas |
| US6503703B1 (en) * | 1995-05-19 | 2003-01-07 | Mount Sinai School Of Medicine Of New York University | Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication |
| PT1003850E (pt) * | 1997-06-06 | 2009-08-13 | Dynavax Tech Corp | Inibidores da actividade de sequências de adn imunoestimulantes |
| US6797462B1 (en) | 1998-06-23 | 2004-09-28 | Uab Research Foundation | Cell-based assay for immunodeficiency virus infectivity and sensitivity |
| US6586207B2 (en) * | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| US7323174B1 (en) * | 2000-06-12 | 2008-01-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulation of immune response and methods based thereon |
| US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| CA2454618C (en) | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| US7368114B2 (en) * | 2001-10-25 | 2008-05-06 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion protein including of CD4 |
| GB0208041D0 (en) * | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
| CA2565259A1 (en) | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
| US20080146495A1 (en) * | 2005-03-11 | 2008-06-19 | The Regents Of The University Of California | Methods for Treating Hiv by Inhibiting Cd4 Down-Modulation |
| US20080283557A1 (en) * | 2007-05-17 | 2008-11-20 | Julianne Desautels | Spout for food stuff container |
| US8912047B2 (en) * | 2011-05-18 | 2014-12-16 | Infineon Technologies Ag | Method for producing a metal layer on a substrate and device |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57144983A (en) * | 1981-02-27 | 1982-09-07 | Otsuka Pharmaceut Factory Inc | Preparation of physiologically active substance |
| US4520113A (en) * | 1984-04-23 | 1985-05-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions |
| US4663436A (en) * | 1984-04-24 | 1987-05-05 | Scripps Clinic And Research Foundation | Leukemia-associated virus immunogen, vaccine and assay |
| US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
| ATE135747T1 (de) * | 1986-08-21 | 1996-04-15 | Univ Columbia | Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids |
| US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
-
1988
- 1988-02-24 US US07/160,348 patent/US5110906A/en not_active Expired - Lifetime
-
1989
- 1989-02-24 DE DE198989103297T patent/DE330227T1/de active Pending
- 1989-02-24 PT PT89838A patent/PT89838B/pt not_active IP Right Cessation
- 1989-02-24 JP JP1503131A patent/JPH02503269A/ja active Pending
- 1989-02-24 AU AU40718/89A patent/AU628072B2/en not_active Ceased
- 1989-02-24 EP EP19890103297 patent/EP0330227A3/en not_active Withdrawn
- 1989-02-24 WO PCT/US1989/000762 patent/WO1989008143A1/en active IP Right Grant
- 1989-02-24 ZA ZA891456A patent/ZA891456B/xx unknown
- 1989-02-24 HU HU891839A patent/HU213019B/hu not_active IP Right Cessation
- 1989-02-24 ES ES198989103297T patent/ES2031805T1/es active Pending
- 1989-02-24 NZ NZ228127A patent/NZ228127A/xx unknown
- 1989-02-24 KR KR1019890701958A patent/KR900700592A/ko not_active Application Discontinuation
- 1989-10-24 DK DK198905282A patent/DK175816B1/da not_active IP Right Cessation
- 1989-10-24 FI FI895049A patent/FI102837B/fi not_active IP Right Cessation
-
1991
- 1991-09-17 GR GR90300099T patent/GR900300099T1/el unknown
-
1992
- 1992-02-05 US US07/830,489 patent/US5422274A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU4071889A (en) | 1989-09-22 |
| DK528289A (da) | 1989-12-22 |
| FI895049A0 (fi) | 1989-10-24 |
| US5422274A (en) | 1995-06-06 |
| HUT52814A (en) | 1990-08-28 |
| FI102837B1 (fi) | 1999-02-26 |
| DK175816B1 (da) | 2005-03-07 |
| PT89838A (pt) | 1989-10-04 |
| US5110906A (en) | 1992-05-05 |
| AU628072B2 (en) | 1992-09-10 |
| GR900300099T1 (en) | 1991-09-27 |
| EP0330227A2 (en) | 1989-08-30 |
| FI102837B (fi) | 1999-02-26 |
| DK528289D0 (da) | 1989-10-24 |
| JPH02503269A (ja) | 1990-10-11 |
| PT89838B (pt) | 1994-02-28 |
| EP0330227A3 (en) | 1991-01-30 |
| KR900700592A (ko) | 1990-08-16 |
| WO1989008143A1 (en) | 1989-09-08 |
| DE330227T1 (de) | 1990-09-27 |
| HU213019B (en) | 1997-01-28 |
| NZ228127A (en) | 1991-11-26 |
| ZA891456B (en) | 1990-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2031805T1 (es) | Derivados del t-4 soluble. | |
| ES554967A0 (es) | Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido. | |
| ATE144704T1 (de) | Mittel zur topischen verabreichung von arzneiwirkstoffen | |
| HUT55050A (en) | Process for producing albumin derivatives and pharmaceutical compositions comprising same | |
| RU95113492A (ru) | Терапевтическая комбинация, содержащая человеческий интерферон, его применение, фармацевтический препарат, упаковка и способ лечения | |
| ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
| ATE189400T1 (de) | Knochenwachstumsfördernde zusammensetzung | |
| NZ229518A (en) | Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment | |
| RU92016463A (ru) | Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе | |
| IT1170214B (it) | Composizione farmaceutica per la cura delle arteriopatie periferiche | |
| IT1255723B (it) | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
| ES2053454T3 (es) | Composiciones farmaceuticas que contienen peptidos del grupo de la colecistoquinina-ceruleina para la terapia de estados de shock y de insuficiencias respiratorias y cardiocirculatorias. | |
| DK0573492T3 (da) | Præparater indeholdende fluticasonpropionat og oxiconazol eller salte deraf til topisk administration | |
| KR910005858A (ko) | 지방산 요법 | |
| GR1000419B (el) | Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου. | |
| IT1205349B (it) | Determinate pirazolo-chinoline sostituite,procedimento per la loro preparazione,preparati farmaceutici contenenti questi composti e loro impiego terapeutico | |
| ES2059312T3 (es) | Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion. | |
| DE3486191D1 (de) | Arzneimittel mit systematischer anticholinesterasischer, agonistisch-cholinergischer und antimuskariner wirkung. | |
| DK0484112T3 (da) | Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum | |
| IT1200944B (it) | Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico | |
| IT1231342B (it) | Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono | |
| IT1168778B (it) | Impiego di derivati dello zucchero per la profilassi e terapia di infezioni da virus e preparati farmaceutici che contengono tali composti | |
| DE58904108D1 (de) | Arzneimittel. | |
| IT8748235A0 (it) | Peptidi e derivati peptidici, loro preparazione e loro impiego come medicamenti | |
| SE8804640D0 (sv) | Medicament comprising cyclolinopeptide a |